|Articles|September 25, 2015
Lecia V. Sequist on Side Effects From Agents for Resistant Lung Cancer
Author(s)Lecia V. Sequist
Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).
Advertisement
Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291), two agents specific to acquired T790M mutations in EGFR-positive non-small cell lung cancer (NSCLC).
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Doctor Outlines Cervical Cancer Care, Side Effects, HPV Prevention
2
FDA to Review New Drug Combo for Previously Treated Metastatic Colorectal Cancer
3
Erleada Shows Survival Advantage in Real-World Study of Metastatic Prostate Cancer
4
Expert Insights: FDA Approval of Lymphir for Cutaneous T-Cell Lymphoma
5